Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM81D4I)

Drug Name
PF-4447943 Drug Info
Synonyms BCP16255
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Sickle-cell disorder 3A51 Phase 1 [2]
Cross-matching ID
PubChem CID
135564558
CAS Number
CAS 1082744-20-4
TTD Drug ID
DM81D4I

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 9 (PDE9) TTZOEBC PDE9A_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Phosphodiesterase 9 (PDE9) DTT PDE9A 1.807 8.131 3.263 2.7
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 9 (PDE9) DTT PDE9A 8.73E-03 0.07 0.36
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00930059) A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.